A chromone–deferiprone compound 25c was created as a promising lead for AD therapy, which displayed hMAO-B inhibition (IC50 = 1.58 μM), iron-chelating (pFe3+ = 18.79), antioxidant, anti-ferroptosis, and improving the cognitive impairment abilities.
Alzheimer's disease (AD) is a multifactorial neurological disorder that affects millions of people worldwide.
A total of 18 heterocyclic derived conjugated dienones (CD1–CD18) were evaluated for their potential monoamine oxidase (MAO)-A/-B inhibitory activity.
Indazoles as privileged scaffolds; synthetic strategies; clinical trial compounds; biological activities: anti-tubercular, antifungal, antibacterial, antileishmanial, anti-Parkinson's, anti-inflammatory, antidiabetic, and anticancer.
Inhibition of monoamine oxidase-B (MAO-B) decelerates the breakdown of dopamine in the brain, consequently augmenting dopaminergic neurotransmission, which is a critical pathway for ameliorating motor symptomatology of Parkinson's disease (PD).